{
    "title": "GSK sees $500 mln peak sales for yeast infection pill licensed from Scynexis",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11920521/GSK-sees-500-mln-peak-sales-yeast-infection-pill-licensed-Scynexis.html",
    "date": "2023-03-30",
    "keywords": [
        "gsk",
        "scynexis",
        "treatment",
        "maggie",
        "drug",
        "company",
        "deal",
        "wednesday",
        "pill",
        "brexafemme",
        "pharma",
        "product",
        "candidiasis",
        "infection",
        "latestage",
        "march",
        "drugmaker",
        "executive",
        "quarter",
        "year",
        "officer",
        "luke",
        "experience",
        "building",
        "awareness",
        "trajectory",
        "time",
        "episode",
        "yeast",
        "disease",
        "control",
        "prevention",
        "food",
        "administration",
        "regulator",
        "statement",
        "part",
        "difficulty",
        "investment",
        "function",
        "scale",
        "record",
        "care",
        "blockbuster",
        "shingrix",
        "agreement",
        "medication",
        "fungal",
        "indication",
        "development",
        "gepotidacin",
        "tract",
        "number",
        "research",
        "nextgeneration",
        "breakthrough",
        "rise",
        "misuse",
        "overuse",
        "fick",
        "editing",
        "mark",
        "potter"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}